Skip to main content
Clinical Trials/NCT05556941
NCT05556941
Completed
Not Applicable

Development and Efficacy of Metacognitive Intervention for Individuals With Severe Mental Disorders

University of Haifa0 sites84 target enrollmentOctober 1, 2015
ConditionsSchizophrenia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
University of Haifa
Enrollment
84
Primary Endpoint
Positive and Negative Syndrome Scale
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The overall aim of this study was to develop a meta-cognitive group intervention in order to apply it and to understand and distinguish the components that influence participation among people with schizophrenia

Detailed Description

The overall aim of this study was to develop a Meta cognitive group intervention in order to apply it and to understand and distinguish the components that influence participation among people with schizophrenia. The specific objectives were to: 1. Improve participation by increasing the effectiveness of cognitive strategy use and teaching clients to independently review performance and to examine the strategy's effectiveness. 2. Compare the use of cognitive strategies between participants with schizophrenia and their matched controls following the Meta cognitive group intervention and to correlate the cognitive strategies use and participation following the Meta cognitive group. 3. Examine whether symptoms moderate the association between metacognitive outcomes and participation among people with schizophrenia following the Meta cognitive group.

Registry
clinicaltrials.gov
Start Date
October 1, 2015
End Date
April 30, 2016
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Naomi Josman

Prof

University of Haifa

Eligibility Criteria

Inclusion Criteria

  • Confirmed diagnosis of schizophrenia by a licensed psychiatrist
  • Fluency in Hebrew
  • t-score of at least 65 on the Behavior Rating Inventory of Executive Function-Adult version

Exclusion Criteria

  • Severe psychiatric hospitalization of over 24 hours during the month prior to the beginning of the study
  • Used drugs or alcohol

Outcomes

Primary Outcomes

Positive and Negative Syndrome Scale

Time Frame: 15 minutes

The Positive and Negative Syndrome Scale is a 30-item scale with seven positive and seven negative symptoms items and 16 psychopathological items. The severity of each item is rated on a scale from 1 (none) to 7 (most severe). A general Positive and Negative Syndrome Scale score is between 30 (lack of symptoms) and 210 (very severe state of the disease). Potential ranges are 7 to 49 for the positive and negative symptom scales and from 16 to 12 for the general psychopathology scale.

Similar Trials